Company: CERO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001213900-25-010230
Chunk: 228

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 228
---
 following the fifth anniversary of the date of the first sale of shares of PBAX Class A Common Stock in its initial public offering, (ii) the last day of the fiscal year in which the Company has more than $1.07 billion in total annual gross revenues, (iii) the date on which the Company is deemed to be a “large accelerated filer” under the rules of the SEC, which means the market value of the Common Stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, or (iv) the date on which the Company has issued more than $1.0 billion of non-convertible debt over the prior three-year period. The Company may choose to take advantage of some but not all of these reduced reporting burdens. Accordingly, the information contained herein may be different than you might obtain from other public companies. 141 MANAGEMENT OF CERO Executive Officers and Directors As of December 2, 2024, our directors and executive officers were as follows:

| Name                   |     | Age |     | Title                                |
| Executive Officers:    |     |     |     |                                      |
| Chris Ehrlich          |     |  54 |     | Chairman and Chief Executive Officer |
| Andrew “Al” Kucharchuk |     |  44 |     | Chief Financial Officer              |
| Kristen Pierce         |     |  54 |     | Chief Development Officer            |
| Directors:             |     |     |     |                                      |
| Brian G. Atwood        |     |  72 |     | Director                             |
| Michael Byrnes         |     |  48 |     | Director                             |
| Kathleen LaPorte       |     |  63 |     | Director                             |
| Lindsey Rolfe, M.D.    |     |  56 |     | Director                             |
| Shami Patel            |     |  55 |     | Director                             |

Executive Officers Chris Ehrlichhas served as our Chairman and Chief Executive Officer since December 2024. From October 2024 to November 2024, he served as the interim Chairman and Chief Executive Officer. Prior to this, he served as the Vice Chairman of our board of directors from February 2024 to October 2024. He previously served as the Chief Executive Officer of PBAX from October 2021 until the Closing of the Business Combination in February 2024. From January 2021 to August 202